NGS revealed that 46 (37.7%) patients harbored both SF3B1 and MPN driver mutations, 2 of whom had simultaneous mutations in SF3B1, JAK2, and MPL. Among patients with both SF3B1 and MPN driver mutations, 22 (47.8%), 13 (28.3%) and 11 (23.9%) patients exhibited SF3B1 mutation dominance, no dominance, and MPN driver mutation dominance, respectively (Supplementary Fig. S2). Here, JAK2 is linked to myeloproliferative neoplasm.